How many employees does AxoGen have this year?
AxoGen has 346 undefined employees this year.
AxoGen Employees 2025
AxoGen Employees
346
Ticker
AXGN
ISIN
US05463X1063
WKN
A1JMHK
In 2025, AxoGen employed 346 people, a 0% change from the 346 number of employees in the previous year.
AxoGen Aktienanalyse
What does AxoGen do?
AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Employees Details
Examining AxoGen's Employee Base
AxoGen's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding AxoGen's operational capacity and future potential.
Year-to-Year Comparison
Assessing AxoGen's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.
Impact on Investments
AxoGen's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.
Interpreting Employee Trends
Fluctuations in AxoGen’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.
Frequently Asked Questions about AxoGen stock
How many employees did AxoGen have compared to the previous year?
Compared to the previous year, AxoGen had 0% more employees.
What impact did the number of employees have on the company AxoGen?
The number of employees has a direct impact on the efficiency and productivity of AxoGen. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.
What impact did the number of employees have on investors of AxoGen?
The number of employees can also have an impact on investors of AxoGen, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.
How does an increase in equity capital of AxoGen affect the company?
An increase in equity of AxoGen can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.
How does a reduction in AxoGen's equity affect the company?
A reduction in equity of AxoGen can impair its financial stability and decrease its ability to fulfill future investments and obligations.
What are some factors that influence the equity of AxoGen?
Some factors that can influence the equity of AxoGen include, among others, revenue development, profit and loss statement, dividend payments, and investments.
Why is the equity of AxoGen so important for investors?
The equity of AxoGen is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.
How does the number of employees at AxoGen influence the company?
The number of employees at AxoGen can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.
How has the number of employees at AxoGen evolved in recent years?
In recent years, the number of employees at AxoGen has changed by 0.
How many employees does AxoGen currently have?
AxoGen currently has 346 undefined employees.
Why is the number of employees important for investors of AxoGen?
The number of employees is important for investors of AxoGen as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.
What strategic measures can AxoGen take to change the number of employees?
To change the number of employees, AxoGen can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.
How much dividend does AxoGen pay?
Over the past 12 months, AxoGen paid a dividend of 1 USD . This corresponds to a dividend yield of about 6.22 %. For the coming 12 months, AxoGen is expected to pay a dividend of 0 USD.
What is the dividend yield of AxoGen?
The current dividend yield of AxoGen is 6.22 %.
When does AxoGen pay dividends?
AxoGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AxoGen?
AxoGen paid dividends every year for the past 0 years.
What is the dividend of AxoGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is AxoGen located?
AxoGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von AxoGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AxoGen from 2/12/2010 amounting to 1 USD, you needed to have the stock in your portfolio before the ex-date on 1/27/2010.
When did AxoGen pay the last dividend?
The last dividend was paid out on 2/12/2010.
What was the dividend of AxoGen in the year 2024?
In the year 2024, AxoGen distributed 0 USD as dividends.
In which currency does AxoGen pay out the dividend?
The dividends of AxoGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AxoGen
Our stock analysis for AxoGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AxoGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
